Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Metastasectomy, Nephrectomy, Nivolumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
Interventions: Teplizumab, Placebo infusion; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 8 Years to 45 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 17
States / cities: San Francisco, California • Stanford, California • Denver, Colorado + 13 more

Conditions: Antithrombin Deficiency, Congenital
Interventions: Recombinant Human Antithrombin (rhAT); Biological
Lead sponsor: rEVO Biologics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Marietta, Georgia • Charleston, South Carolina

Conditions: Overweight and Obesity
Interventions: Pecan snack, Tortilla chip snack; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostate Cancer
Interventions: Docetaxel, Imatinib Mesylate, Leuprolide, Goserelin Acetate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Muscle Tone
Interventions: BTL-899 Buttocks; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Gilbert, Arizona • Hackensack, New Jersey • Montclair, New Jersey + 2 more

Conditions: Leukemia
Interventions: White Blood Cell Transfusion; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia
Interventions: Acalabrutinib, Ibrutinib; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years and older
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 31
States / cities: Phoenix, Arizona • Anaheim, California • Berkeley, California + 26 more

Conditions: Diabetes Mellitus Self Management Education, Hyperglycemic Control, High Risk Diabetes
Interventions: Diabetes Self Management Education; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 1
States / cities: Atlanta, Kansas

Conditions: Inflammation, Oxidative Stress, Resistance Exercise, Recovery, Exercise Performance Recovery
Interventions: Haskap berry smoothie, Placebo Comparator; Dietary Supplement
Lead sponsor: Montana State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: treosulfan, fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation, tacrolimus, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, methotrexate; Drug · Radiation · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Denver, Colorado • Portland, Oregon • Seattle, Washington

Conditions: Prostate Cancer
Interventions: bicalutamide, goserelin, mitoxantrone hydrochloride, prednisone; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 983 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2018
U.S. locations: 234
States / cities: Anchorage, Alaska • Glendale, Arizona • Phoenix, Arizona + 157 more

Conditions: Muscular Hypertrophy
Interventions: high protein milk, Placebo; Dietary Supplement
Lead sponsor: Marymount University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride; Drug · Biological · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
Interventions: ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration; Drug · Procedure · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 12 Months to 22 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Hypertension
Interventions: Hydrochlorothiazide, Trandolapril; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension
Interventions: Virtual Hypertension Clinic; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Vertebral Metastasis
Interventions: Conformal High Dose Intensity Modulated Radiation Therapy; Radiation
Lead sponsor: Ronald McGarry; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Standard of care; Biological · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 78
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more

Conditions: Low Protein Dietary Intake, High Protein Dietary Intake
Interventions: Meal Patterning; Other
Lead sponsor: Purdue University; Other
Eligibility: 21 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Melanoma
Interventions: Ipilimumab, Nivolumab, Placebo matching Ipilimumab, Placebo matching Nivolumab; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 15 Years and older
Enrollment: 906 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 35
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 27 more

Conditions: Esophageal Motility Disorders
Interventions: Not listed
Lead sponsor: Lexington Health Incorporated; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: West Columbia, South Carolina

Conditions: Solid Tumor, High-grade Glioma, Leptomeningeal Metastasis
Interventions: Azeliragon, CSI; Drug · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Mountain Sickness and Fatigue
Interventions: Aminophylline 400 mg, Ambrisentan 5 mg, Placebo; Drug · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 50 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Durham, North Carolina

Search by objective public record fields.

Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery

Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

Effects of Pecan Nut Snacks v Equicaloric Snacks on Appetite, Food Intake, Metabolism, Hormones and Biomarkers

Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

High-Intensity Focused Electromagnetic Procedure and Radiofrequency for Toning of Buttocks

A Feasibility Study of Prophylactic White Blood Cell Transfusions

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Disease Management and Educational Intervention Outcomes in High-Risk Diabetics

Impact of Haskap Berries on Recovery From High Intensity Resistance Training

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia

S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer

Resistance Training and Milk Supplementation

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)

Virtual Hypertension Clinic

Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine

Open Label Study of Long Term Evaluation Against LDL-C Trial

The Body's Response to Changes in Dietary Protein and Meal-Frequency In Men

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Establishing a Correlation Between HRM and UGI MM Studies

Concurrent Azeliragon With Craniospinal Irradiation

A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude